Trials / Completed
CompletedNCT05242458
A Study of Ustekinumab Treatment in Children With Crohn's Disease
Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children With Crohn's Disease: A Retrospective Cohort Study Using the ImproveCareNow Registry Data
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 545 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 2 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\<\] 18 years and weight \>= 40 kilograms \[kg\] at baseline).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ustekinumab | No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice. |
Timeline
- Start date
- 2022-03-21
- Primary completion
- 2023-05-22
- Completion
- 2023-05-22
- First posted
- 2022-02-16
- Last updated
- 2025-05-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05242458. Inclusion in this directory is not an endorsement.